C. Chan

发表

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

M. Percival, D. Riendeau, B. Kennedy, 1999, Bioorganic & medicinal chemistry letters.

A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors

C. Brideau, C. Chan, S. Kargman, 1996, Inflammation Research.

Peptoid inhibition of trypanothione reductase as a potential antitrypanosomal and antileishmanial drug lead

A. Fairlamb, C. Chan, K. Douglas, 2002, Amino Acids.

Specific peptide inhibitors of trypanothione reductase with backbone structures unrelated to that of substrate: potential rational drug design lead frameworks

A. Fairlamb, C. Chan, K. Douglas, 2001, Amino Acids.

Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.

M Read, J. E. Hyde, W. Sirawaraporn, 1998, Journal of medicinal chemistry.

L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.

D. Denis, C. Chan, S. Charleson, 1989, Canadian journal of physiology and pharmacology.

A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.

P. Prasit, C. Brideau, C. Chan, 1993, Journal of lipid mediators.

Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.

D. Riendeau, D. Denis, P. Prasit, 1992, Canadian journal of physiology and pharmacology.

Selective inhibitors of COX-2.

J. Falgueyret, B. Kennedy, C. Chan, 1995, Agents and actions. Supplements.

Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.

D. Riendeau, C. Brideau, C. Chan, 1999, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of 5,6-diarylimidazo[2.1-b]thiazole as selective COX-2 inhibitors

D. Riendeau, P. Prasit, C. Brideau, 1997 .

From indomethacin to a selective COX-2 inhibitor. Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors.

P. Prasit, C. Chan, S. Charleson, 1997, Advances in experimental medicine and biology.

Cyclooxygenase-2 inhibitors. Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives.

C. Chan, A. Ford-hutchinson, J. Gauthier, 1995, Journal of medicinal chemistry.

Quinolines as potent 5-lipoxygenase inhibitors: synthesis and biological profile of L-746,530.

J. Falgueyret, D. Riendeau, R. Young, 1998, Bioorganic & medicinal chemistry letters.

A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.

D. Riendeau, P. Prasit, C. Brideau, 1999, Bioorganic & medicinal chemistry letters.

SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor.

D. Riendeau, S. Boyce, P. Prasit, 1999, Bioorganic & medicinal chemistry letters.

Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).

D. Riendeau, R. Young, P. Prasit, 2000, Bioorganic & medicinal chemistry letters.

2-heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors.

D. Riendeau, C. Brideau, C. Chan, 1999, Bioorganic & medicinal chemistry letters.

Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.

J. Falgueyret, D. Riendeau, C. Brideau, 1994, Journal of medicinal chemistry.

Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.

J. Falgueyret, D. Riendeau, C. Brideau, 1996, Journal of medicinal chemistry.

2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.

R Gordon, D. Riendeau, P. Prasit, 1999, Journal of medicinal chemistry.

A general synthetic approach to amaryllidaceae alkaloids

C. Chan, C. W. Bird, A. Brown, 1989 .

In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats.

C. Brideau, C. Chan, C Brideau, 2001, American journal of veterinary research.

Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.

A. Fairlamb, V. Yardley, S. Croft, 1998, Journal of medicinal chemistry.

2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.

R Gordon, R Fortin, D. Riendeau, 1998, Bioorganic & medicinal chemistry letters.

The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors.

C. Chan, B. Dymock, J. Scicinski, 1996, Journal of medicinal chemistry.

Substituted heterocyclic analogs as selective COX-2 inhibitors in the flosulide class.

D. Riendeau, P. Prasit, C. Chan, 1999, Bioorganic & medicinal chemistry letters.

Oxidative bioactivation of the lactol prodrug of a lactone cyclooxygenase-2 inhibitor.

J. Falgueyret, D. Riendeau, Z. Wang, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors.

C. Chan, G. Inglis, B. E. Kirk, 1993, Journal of medicinal chemistry.

Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816.

J. Falgueyret, D. Riendeau, C. Brideau, 1993, Journal of medicinal chemistry.

Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines.

D. Marks, V. Yardley, S. Croft, 2000, Journal of medicinal chemistry.

Discovery of MC-02,331, a new cephalosporin exhibiting potent activity against methicillin-resistant Staphylococcus aureus.

C. Chan, F. Malouin, A. Boggs, 1998, The Journal of antibiotics.

Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs.

C. Brideau, C. Chan, I. Rodger, 1998, Journal of cardiovascular pharmacology.

A New Series of Selective COX-2 Inhibitors: 5,6-Diarylthiazolo(3,2-b)( 1,2,4)triazoles.

P. Prasit, C. Brideau, C. Chan, 1997 .

A new series of selective COX-2 inhibitors : 5,6-diarylthiazolo[3,2-b][1,2,4]triazoles

P. Prasit, C. Brideau, C. Chan, 1997 .

NOVEL 1,2-DIARYLCYCLOBUTENES : SELECTIVE AND ORALLY ACTIVE COX-2 INHIBITORS

D. Riendeau, C. Chan, W. Cromlish, 1996 .

Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.

J. Falgueyret, D. Riendeau, C. Brideau, 1994, Journal of Medicinal Chemistry.

Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors.

D. Riendeau, P. Prasit, C. Brideau, 1999, Bioorganic & medicinal chemistry letters.